Physician profile
Peter E Hoffman
NPI 1952324139
$930.67
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.85 · 2020: $55.38 · 2021: $286 · 2022: $171 · 2023: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $297.50 | 2020-2023 | Jardiance, Emgality |
| Abbvie INC. | $98.12 | 2022-2023 | |
| Pfizer INC. | $98.01 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.07 | 2022 | |
| Abbott Laboratories | $47.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.69 | 2021 | |
| Novo Nordisk INC | $42.60 | 2021 | |
| Exact Sciences Corporation | $30.75 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $30.08 | 2023 | Arexvy |
| Amarin Pharma, INC. | $20.07 | 2020 | |
| Circassia INC. | $16.86 | 2019 | |
| Genentech USA, INC. | $15.63 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.17 | 2023 | Prehevbrio |
| Merck Sharp & Dohme LLC | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.